Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $444.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented, "ALNY ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
